News headlines about DelMar Pharmaceuticals (NASDAQ:DMPI) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DelMar Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.8492335488654 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

DMPI has been the subject of several research analyst reports. ValuEngine upgraded DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 23rd.

Shares of DMPI traded down $0.02 on Tuesday, hitting $0.53. The company’s stock had a trading volume of 81,900 shares, compared to its average volume of 336,145. DelMar Pharmaceuticals has a fifty-two week low of $0.33 and a fifty-two week high of $2.29. The firm has a market capitalization of $12.00 million, a PE ratio of -0.72 and a beta of 1.78.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Further Reading: Fundamental Analysis and Individual Investors

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.